← Trials/Trial dossier/NCT04205539

WithdrawnPhase 1

Lymphatic System Health in Alzheimer's Disease

Lead sponsor

Neurological Associates of West Los Angeles

Asset

Dexmedetomidine

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Age 18-90

Primary endpoints

•T1 fMRI Imaging•T1 fMRI Imagine•Diffusion Tensor Imaging

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study ID20190858

NCT IDNCT04205539

Timeline

Milestones

Study first posted2019-12-19actual

Study start2021-12-10estimated

Last update posted2022-09-28actual

Primary completion2022-12-10estimated

Study completion2023-12estimated (month precision)

Assets

Drug assets

Dexmedetomidine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age90 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•In order for a subject to be considered for this study, the subject must be willing to comply with the study protocol. They must be between 18 and 90 years old. They must complete neurocognitive testing to assess cognitive impairment (QDRS and RBANS)

Exclusion criteria

•Advanced stages of any terminal illness or any active cancer that requires chemotherapy

•Hepatic impairment

•Significant cytopenia

•Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis

•Women who are pregnant, may become pregnant, or are breastfeeding

•Any counter indications to dexmedetomidine

•Subjects unable to give informed consent or in vulnerable categories, such as prisoners

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Neuroimaging

Global cognition

2 endpoints

Secondary/protocol endpoint

Repeatable Battery Assessment of Neuropsychological Status (RBANS) versions A-D

Time frame:1 week prior to dexmedetomidine

categorical status, descriptive

Secondary/protocol endpoint

Quick Dementia Rating Scale (QDRS)

Time frame:1 week prior to dexmedetomidine

descriptive

Neuroimaging

4 endpoints

Primary/protocol endpoint

T1 fMRI Imaging

Time frame:Before dexmedetomidine

descriptive

Primary/protocol endpoint

T1 fMRI Imagine

Time frame:Immediately following administration of dexmedetomidine

descriptive

Primary/protocol endpoint

Diffusion Tensor Imaging

Time frame:Before dexmedetomidine administration

descriptive

Primary/protocol endpoint

Diffusion Tensor Imaging

Time frame:Immediately following administration of dexmedetomidine

descriptive

Publications (22)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.